Search

This article provides information on the diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a rare immune-mediated neuropathy. It discusses the challenges in diagnosing CIDP when there is no clear evidence of demyelination and presents a study that explores the response to treatment in these cases. The article emphasizes the importance of early recognition and treatment of CIDP to prevent disability, while also acknowledging the risks of overdiagnosis and unnecessary treatment. It concludes that treatment decisions should be based on a physician's assessment of the patient's clinical presentation and the severity of symptoms. The document also includes a list of references to scientific articles that discuss various aspects of CIDP, providing further information for those conducting research on the topic. [Extracted from the article]

Introduction/Aim: High‐resolution ultrasound (HRUS) is increasingly used in evaluating neuromuscular conditions. Its potential advantages include its ability to discern anatomic information and make specific etiological diagnoses. Although many studies have demonstrated HRUS effectiveness, especially in mononeuropathies, more information is needed to better determine how often and to what extent useful information is obtained; how it influences diagnosis, clinical decision‐making, and patient management; and how it is used with electrodiagnostic (EDx) studies. Methods: A retrospective cohort study was performed on patients referred for HRUS at a university laboratory during 2021. Demographic information, referral diagnoses, clinical information, HRUS findings, and follow‐up patient management were analyzed. For patients who had EDx, results were compared with HRUS. Determinations were made whether HRUS did or did not aid in the diagnosis. For patients in whom HRUS resulted in a diagnosis, determination was made whether it confirmed the diagnosis made clinically or by EDx but did not change management; added additional important information; and/or made a decisive impact on subsequent management. Results: Five hundred two patients were analyzed, most referred for mononeuropathy, brachial plexopathy, and polyneuropathy. HRUS was abnormal in 81.7% of patients. HRUS added additional useful information in 79.0% and was decisive in management in 62.7%. In patients who also had abnormal EDx, HRUS resulted in decisive management in 49.5%. Discussion: HRUS is an effective diagnostic tool that frequently adds localizing and structural information that is otherwise not obtainable by clinical and EDx evaluation. In a substantial number of patients selected for HRUS, it is decisive in guiding further management. See article on pages 255–256 in this issue. [ABSTRACT FROM AUTHOR]